临床医生引导的数字CBT-I改善失眠合并OSA患者的睡眠质量与呼吸暂停严重程度:双盲随机临床试验
这项双盲随机临床试验纳入88例失眠合并阻塞性睡眠呼吸暂停(COMISA)患者,比较临床医生引导的数字认知行为治疗(D-CBT-I)与睡眠卫生教育(SHE)的效果。3个月随访时,D-CBT-I组在失眠严重指数和匹兹堡睡眠质量指数上改善显著优于SHE组,并降低主观嗜睡;治疗后呼吸暂停低通气指数也显著下降。结论认为D-CBT-I可改善COMISA患者的失眠和OSA严重程度及认知功能。
要点
- 临床医生引导的D-CBT-I在3个月随访时显著改善COMISA患者的失眠严重程度和睡眠质量。
- D-CBT-I在治疗后显著降低呼吸暂停低通气指数,并减少主观嗜睡。
- 治疗第2-4周可能出现ESS短暂升高,但未报告功能损害或嗜睡相关不良事件。
核心结论
- 临床医生引导的D-CBT-I改善了COMISA患者的失眠和OSA严重程度,并增强了认知功能。
研究设计与样本
- 双盲随机临床试验,共纳入88例COMISA患者,比较临床医生引导的D-CBT-I(6次每周在线课程)与单纯睡眠卫生教育(SHE)。
- 在基线、治疗后(6周)和3个月随访时进行盲法结局评估。
主要发现
- 3个月随访时,意向性治疗分析显示D-CBT-I组较SHE组在ISI上改善更显著(-9.5 vs. -4.0分;d = -1.18,P = 0.001)。
- 3个月随访时,D-CBT-I组较SHE组在PSQI上改善更显著(-4.9 vs. -1.8分;d = -0.87,P = 0.001)。
- 3个月随访时,D-CBT-I组较SHE组降低主观嗜睡更显著(ESS:-3.4 vs. -1.0分;d = -0.68,P < 0.001)。
- 治疗后,D-CBT-I组较SHE组降低呼吸暂停低通气指数(实验室多导睡眠监测:-6.0 vs. +2.0 events/h;d = -0.64,P = 0.019)。
- 治疗第2-4周出现ESS短暂升高,但未报告功能损害或嗜睡相关不良事件;在元认知和执行功能方面观察到额外获益。
临床怎么用
- 对于COMISA患者,临床医生引导的D-CBT-I可作为改善失眠和OSA严重程度的一种治疗选择。
- 治疗过程中需关注第2-4周可能出现的短暂嗜睡加重,但本研究中未报告相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Cognitive behavioral therapy for insomnia (CBT-I) is the accepted first-line treatment for insomnia, but its scalability and safety in patients with co-morbid insomnia and obstructive sleep apnea (COMISA) remain unclear. Clinician-guided digital CBT-I (D-CBT-I) is a potential treatment option that may address these limitations in COMISA. OBJECTIVE: To evaluate the effectiveness of clinician-guided D-CBT-I versus sleep hygiene education (SHE) in patients with COMISA. METHODS: This randomized trial (n = 88) compared clinician-guided D-CBT-I (6 weekly online sessions: sleep restriction, sleep hygiene, stimulus control, cognitive restructuring, relapse prevention) with SHE alone. Blinded outcome assessments were conducted at baseline, posttreatment (6 weeks), and 3-month follow-up. Primary outcomes were Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) scores at posttreatment and 3-month follow-up. Secondary outcomes included daytime sleepiness, sleep parameters, OSA severity, neurocognitive function, and adverse events. MEASUREMENTS AND MAIN RESULTS: At 3-month follow-up, intention-to-treat analysis showed significantly greater improvements with D-CBT-I versus SHE on ISI (-9.5 vs. -4.0 points; d = -1.18, P = 0.001) and PSQI (-4.9 vs. -1.8 points; d = -0.87, P = 0.001); D-CBT-I also reduced subjective sleepiness (Epworth Sleepiness Scale; -3.4 vs. -1.0 points; d = -0.68, P < 0.001). At posttreatment, D-CBT-I reduced the apnea-hypopnea index (attended in-laboratory polysomnography; -6.0 vs. +2.0 events/h; d = -0.64, P = 0.019). Although transient increases in ESS occurred at weeks 2-4, no functional impairment or sleepiness-related adverse events were reported. Additional benefits were observed in metacognition and executive function. CONCLUSION: Clinician-guided D-CBT-I improved insomnia and OSA severity, and enhanced cognitive function in COMISA patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry; NO.: ChiCTR2500099854; URL: https://www.chictr.org.cn/showproj.html?proj=267457.
引用
- Shi Y, Feng X, Chen Z, et al. Clinician-guided digital CBT-I improves sleep quality and apnea severity in patients with co-morbid insomnia and OSA: A Double-Blind, Randomized Clinical Trial. Am J Respir Crit Care Med. 2026. PMID: 42958645. doi:10.1093/ajrccm/aamag567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。